Current Report Filing (8-k)
May 01 2019 - 2:42PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
Current
Report Pursuant
to
Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported) April 25, 2019
PRESSURE
BIOSCIENCES, INC.
|
(Exact
Name of Registrant as Specified in its Charter)
|
MASSACHUSETTS
|
(State
or Other Jurisdiction of Incorporation)
|
001-38185
|
|
04-2652826
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
14
Norfolk Avenue, South Easton, MA
|
|
02375
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
(508)
230-1828
|
(Registrant’s
Telephone Number, Including Area Code)
|
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (
see
General Instruction A.2. below):
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
of Certain Officers.
Departure
of Officer and Designation of Successor
On
April 25, 2019, Mr. Richard T. Schumacher, President and Chief Executive Officer (“CEO”) of Pressure BioSciences,
Inc. (the “Company”) informed the Company’s Board of Directors (the “Board”) that he plans to step
down as President and CEO, effective September 9, 2019. Mr. Schumacher is expected to continue to serve as a member of the Board.
After September 9, 2019, Mr. Schumacher is expected to serve as a senior consultant to the Company for at least one year.
On
May 1, 2019, the Company announced that the Board has designated Bradford A. Young, Ph.D., MBA to succeed Mr. Schumacher as the
Company’s President and CEO, effective September 9, 2019. Dr. Young has been the Company’s Senior Vice President and
Chief Commercial Officer since November 2018. A copy of the press release announcing Mr. Schumacher’s transition to a new
role and Dr. Young’s designation is furnished as Exhibit 99.1 to this report.
Item
9.01 Financial Statements and Exhibits
(d)
Exhibits
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Dated:
May 1, 2019
|
PRESSURE
BIOSCIENCES, INC.
|
|
|
|
By:
|
/s/
Richard T. Schumacher
|
|
|
Richard
T. Schumacher,
|
|
|
President
and Chief Executive Officer
|
Pressure Biosciences (CE) (USOTC:PBIO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Pressure Biosciences (CE) (USOTC:PBIO)
Historical Stock Chart
From Sep 2023 to Sep 2024